TAC VERSUS FAC AS ADJUVANT CHEMOTHERAPY FOR HIGH-RISK NODE-NEGATIVE BREAST CANCER: RESULTS OF THE GEICAM 9805 TRIAL

被引：0
|
作者：
Martin, M. [1 ]
Lluch, A. [2 ]
Segui, M. A. [3 ]
Ruiz, A. [4 ]
Ramos, M. [5 ]
Adrover, E. [6 ]
Rodriguez-Lescure, A. [7 ]
Grosse, R. [8 ]
Calvo, L. [9 ]
Anton, A. [10 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Clin Valencia, Valencia, Spain
[3] Corp Sanit Parc Tauli, Sabadell, Spain
[4] Inst Valenciano Oncol, Valencia, Spain
[5] Ctr Oncol Galicia, La Coruna, Spain
[6] Hosp Gen Alicante, Alicante, Spain
[7] Hosp Gen Univ Elche, Med Oncol Serv, Elche, Spain
[8] Klin & Poliklin, Halle, Germany
[9] Hosp Juan Canalejo, La Coruna, Spain
[10] Hosp Miguel Servet, Zaragoza, Spain
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：77 / 77
页数：1
相关论文
共 50 条
  • [1] Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial
    Martin, M.
    Iluch, A.
    Segui, M.
    Ruiz, A.
    Ramos, M.
    Adrover Cebrian, E.
    Rodriguez-Lescure, A.
    Grosse, R.
    Calvo Martinez, L.
    Anton, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [2] Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study
    Martin, Miguel
    Ruiz, Amparo
    Ruiz Borrego, Manuel
    Barnadas, Agusti
    Gonzalez, Sonia
    Calvo, Lourdes
    Margeli Vila, Mireia
    Anton, Antonio
    Rodriguez-Lescure, Alvaro
    Angel Segui-Palmer, Miguel
    Munoz-Mateu, Montserrat
    Dorca Ribugent, Joan
    Manuel Lopez-Vega, Jose
    Jara, Carlos
    Espinosa, Enrique
    Mendiola Fernandez, Cesar
    Andres, Raquel
    Ribelles, Nuria
    Plazaola, Arrate
    Sanchez-Rovira, Pedro
    Salvador Bofill, Javier
    Crespo, Carmen
    Carabantes, Francisco J.
    Servitja, Sonia
    Ignacio Chacon, Jose
    Rodriguez, Cesar A.
    Hernando, Blanca
    Alvarez, Isabel
    Carrasco, Eva
    Lluch, Ana
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) : 2593 - +
  • [3] Randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial
    Martin, Miguel
    Lluch, Ana
    Ruiz, Amparo
    Ruiz Borrego, Manuel
    Barnadas, Agust
    Gonzalez, Sonia
    Calvo, Lourdes
    Margeli Vila, Mireia
    Anton, Antonio
    Rodriguez-Lescure, Alvaro
    Angel Segu-Palmer, Miguel
    Munoz-Mateu, Montserrat
    Dorca Ribugent, Joan
    Manuel Lopez-Vega, Jose
    Mendiola Fernandez, Cesar
    Andres, Raquel
    Plazaola, Arrate
    Rodriguez, Cesar
    Isabel Casas, Maria
    Maria Carrasco, Eva
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] EFFICACY OF ADJUVANT CHEMOTHERAPY IN HIGH-RISK NODE-NEGATIVE BREAST-CANCER - AN INTERGROUP STUDY
    MANSOUR, EG
    GRAY, R
    SHATILA, AH
    OSBORNE, CK
    TORMEY, DC
    GILCHRIST, KW
    COOPER, MR
    FALKSON, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08): : 485 - 490
  • [5] Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
    Martin, Miguel
    Segui, Miguel A.
    Anton, Antonio
    Ruiz, Amparo
    Ramos, Manuel
    Adrover, Encarna
    Aranda, Ignacio
    Rodriguez-Lescure, Alvaro
    Grosse, Regina
    Calvo, Lourdes
    Barnadas, Agusti
    Isla, Dolores
    Martinez del Prado, Purificacion
    Ruiz Borrego, Manuel
    Zaluski, Jerzy
    Arcusa, Angels
    Munoz, Montserrat
    Lopez Vega, Jose M.
    Mel, Jose R.
    Munarriz, Blanca
    Llorca, Cristina
    Jara, Carlos
    Alba, Emilio
    Florian, Jesus
    Li, Junfang
    Lopez Garcia-Asenjo, Jose A.
    Saez, Amparo
    Jose Rios, Maria
    Almenar, Sergio
    Peiro, Gloria
    Lluch, Ana
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (23): : 2200 - 2210
  • [6] Subtype analysis from the GEICAM/2003-02 study: High-risk, node-negative breast cancer patients treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel
    Rojo, Federico
    Lluch, Ana
    Ruiz, Amparo
    Ruiz-Borrego, Manuel
    Barnadas, Agusti
    Calvo, Lourdes
    Gonzalez, Sonia
    Margeli, Mireia
    Rodriguez-Lescure, Alvaro
    Anton, Antonio
    Angel Segui, Miguel
    Munoz-Mateu, Montserrat
    Dorca, Joan
    Manuel Lopez-Vega, Jose
    Jara-Sanchez, Carlos
    Martin, Nuria
    Casas, Maribel
    Maria Carrasco, Eva
    Caballero, Rosalia
    Martin, Miguel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Adjuvant taxane-based regimen with docetaxel trumps FAC for treatment of high-risk, node-negative breast cancer
    不详
    [J]. FORMULARY, 2011, 46 (01) : 8 - +
  • [8] Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer
    Prakash, Ipshita
    Ben Neely, N.
    Thomas, Samantha M.
    Sammons, Sarah
    Blitzblau, Rachel C.
    DiLalla, Gayle A.
    Hyslop, Terry
    Menendez, Carolyn S.
    Plichta, Jennifer K.
    Rosenberger, Laura H.
    Fayanju, Oluwadamilola M.
    Hwang, E. Shelley
    Greenup, Rachel A.
    [J]. CANCER MEDICINE, 2022, 11 (04): : 1099 - 1108
  • [9] Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC):: An interim safety analysis of the GEICAM 9805 study.
    Martin, M
    Lluch, A
    Seguí, MA
    Antón, A
    Ruiz, A
    Ramos, M
    Rodríguez-Lescure, A
    Adrover, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 32S - 32S
  • [10] ADJUVANT CHEMOTHERAPY FOR NODE-NEGATIVE BREAST-CANCER
    SLEDGE, GW
    MCCASKILLSTEVENS, W
    [J]. CANCER INVESTIGATION, 1992, 10 (06) : 595 - 602
12345